Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-02-06T04:52:35.712Z Has data issue: false hasContentIssue false
  • English
  • Français

Powder X-ray diffraction of 3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone, C15H17N3O4

Published online by Cambridge University Press:  13 August 2015

Qing Wang ,
Bin Tang ,
Pei Xiao Tang ,
Jia Wei He  and
Hui Li
Qing Wang
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Bin Tang
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Pei Xiao Tang
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Jia Wei He
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Hui Li*
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
*
a)Author to whom correspondence should be addressed. Electronic mail: lihuilab@sina.com
Rights & Permissions [Opens in a new window]

Abstract

X-ray powder diffraction data for 3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone, C15H17N3O4, are reported [a = 7.112(1) Å, b = 33.360(2) Å, c = 6.265(1) Å, α = 90°, β = 94.037(1)°, γ = 90°, V = 1483.08 Å3, Z = 4, ρcal = 1.358 g cm−3 and space group P21]. All measured lines were indexed and are consistent with the P21 space group. No detectable impurities were observed.

Keywords

3-(4-Morpholinyl)-1-(4-nitrophenyl)-56-dihydro-2(1H)-pyridinonepharmaceutical intermediateanticoagulantapixaban
Type
Rapid Communication
Information
Powder Diffraction , Volume 30 , Issue 4 , December 2015 , pp. 368 - 369
Check for updates
Copyright
Copyright © International Centre for Diffraction Data 2015 

3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone is an intermediate in the synthesis of the anticoagulant, Apixaban (Jiang and Ji, Reference Jiang and Ji2013; Zikria and Ansell, Reference Zikria and Ansell2009). The sample was prepared using 3,3-Dichloro-1-(4-nitrophenyl)-2-piperidinone and was recrystallized in ethanol and dried. The sample was then ground into powder (HPLC ≥ 98%, ρ = 1.371 g cm−3, T melt = 166–168 °C) and mounted on a flat zero background plate. X-ray powder diffraction measurement was performed at room temperature using an X'Pert PRO diffractometer (PANalytical Co., Ltd., The Netherlands) with a PIXcel 1D detector and CuKα radiation (generator setting: 40 kV and 40 mA). The diffraction data were collected over the angular range from 4° to 50°2θ with a step size of 0.013 13°2θ and a counting time of 30 ms step−1. The software package Material Studio 8.0 (Accelrys Co., Ltd., CA, USA) was used to process the data in the Analytical & Testing Center (Sichuan University, China). The X-ray powder diffraction pattern was pre-treated by subtracting the background, smoothing, and stripping off the Kα 2 component. Automatic indexing results were obtained by DICVOL91 method (Boultif and Louër, Reference Boultif and Louër1991). The following figures of merit were achieved: F 20 = 36.0 (0.0103, 54) (Smith and Snyder, Reference Smith and Snyder1979) and M 20 = 19.1 (de Wolff, Reference de Wolff1968). The preliminary cell from indexing was refined using the Pawley method (Pawley, Reference Pawley1981). Pawley refinement results confirmed that the sample crystallizes in the monoclinic space group P21 (4), with a = 7.112(1) Å, b = 33.360(2) Å, c = 6.265(1) Å, α = 90°, β = 94.037(1)°, γ = 90°, V = 1483.08 Å3, Z = 4, ρ cal = 1.358 g cm−3. Figure 1 shows the powder X-ray diffraction pattern of the compound.

Figure 1. Powder x-ray diffraction pattern of 3-(4-morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone.

ACKNOWLEDGEMENTS

This work was supported by the Applied Basic Research Project of Sichuan Province (Grant no. 2014JY0042), the Testing Platform Construction of Technology Achievement Transform of Sichuan Province (Grant no. 13CGPT0049), and the National Development and Reform Commission and Education of China (Grant no. 2014BW011).

SUPPLEMENTARY MATERIALS

For supplementary material for this article, please visit http://dx.doi.org/10.1017/S0885715615000640

References

Boultif, A. and Louër, D. (1991). “Indexing of powder diffraction patterns for low-symmetry lattices by the successive dichotomy method,” J. Appl. Crystallogr. 24, 987–993.Google Scholar
de Wolff, P. M. (1968). “A simplified criterion for the reliability of a powder pattern,” J. Appl. Crystallogr. 1, 108–113.CrossRefGoogle Scholar
Jiang, J. and Ji, Y. (2013). “Alternate synthesis of apixaban (BMS-562247), an inhibitor of blood coagulation factor Xa,” Synth. Commun. 43(1), 72–79.CrossRefGoogle Scholar
Pawley, G. S. (1981). “Unit-cell refinement from powder diffraction scans,” J. Appl. Crystallogr. 14(6), 357–361.Google Scholar
Smith, G. S. and Snyder, R. L. (1979). “FN: a criterion for rating powder diffraction patterns and evaluating the reliability of powder indexing,” J. Appl. Crystallogr. 12, 60–65.CrossRefGoogle Scholar
Zikria, J. and Ansell, J. (2009). “Oral anticoagulation with factor Xa and thrombin inhibitors: is there an alternative to warfarin?,” Discov. Med. 8(43), 196–203.Google Scholar
Figure 0

Figure 1. Powder x-ray diffraction pattern of 3-(4-morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone.

Supplementary material: File

Wang supplementary material

Wang supplementary material 1

Download Wang supplementary material(File)
File 98.2 KB